Synodos is a first-of-its-kind neurofibromatosis research collaboration dedicated to defeating a variety of forms of neurofibromatosis. To date there are three Synodos efforts funded by Children’s Tumor Foundation (CTF) and supported by Sage. The Synodos model brings together a multidisciplinary team of scientists from world-class labs at academic and medical centers of excellence, who have pledged to work closely together – sharing information, datasets, results and more – at every step in research development, with the goal of speeding up the drug discovery process.
- Synodos NF2 is the first of the Synodos efforts that studies the the rare genetic disorder neurofibromatosis type 2 (NF2) with the end goal of finding new approaches to the diagnosis and treatment of two primary NF2-related tumors: vestibular schwannoma and meningioma.
- Synodos NF1 represents diverse approaches to pre-clinical drug discovery for plexiform neurofibromas that arise in NF1 patients.
- Synodos LGG targets low-grade gliomas that arise in NF1 patients. Together these efforts will create a unified data repository of NF-related research that will be made available to the community to further the development of drugs to treat NF.
Learn more about Synodos on the CTF website.